Stryker Corporation (NYSE:SYK) has been given a $160.00 price target by Cowen and Company in a research report issued on Friday. The brokerage presently has a “buy” rating on the medical technology company’s stock. Cowen and Company’s target price points to a potential upside of 7.38% from the stock’s current price.

SYK has been the topic of a number of other research reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $148.00 target price on shares of Stryker Corporation in a report on Thursday, August 24th. Needham & Company LLC raised Stryker Corporation from an “underperform” rating to a “hold” rating in a report on Friday, August 25th. Cantor Fitzgerald initiated coverage on Stryker Corporation in a report on Thursday, June 29th. They issued a “neutral” rating and a $153.00 target price on the stock. Morgan Stanley reissued an “overweight” rating and issued a $160.00 target price (up previously from $155.00) on shares of Stryker Corporation in a report on Monday, July 10th. Finally, Zacks Investment Research raised Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 target price on the stock in a report on Monday, July 17th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Stryker Corporation currently has a consensus rating of “Hold” and a consensus target price of $146.78.

Stryker Corporation (NYSE SYK) traded up 0.47% during midday trading on Friday, hitting $149.00. The stock had a trading volume of 1,129,048 shares. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $149.23. The firm has a market cap of $55.74 billion, a price-to-earnings ratio of 33.26 and a beta of 0.80. The firm has a 50 day moving average of $142.34 and a 200 day moving average of $139.87.

Stryker Corporation (NYSE:SYK) last released its quarterly earnings data on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the consensus estimate of $1.51 by $0.02. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The company had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.98 billion. During the same period last year, the firm posted $1.39 earnings per share. Stryker Corporation’s revenue was up 6.1% compared to the same quarter last year. Equities research analysts predict that Stryker Corporation will post $6.46 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Stryker Corporation (SYK) Given a $160.00 Price Target by Cowen and Company Analysts” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/06/stryker-corporation-syk-given-a-160-00-price-target-by-cowen-and-company-analysts.html.

In other Stryker Corporation news, insider David Floyd sold 19,305 shares of the firm’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total transaction of $2,790,730.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Graham A. Mclean sold 1,124 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total value of $164,396.24. Following the transaction, the insider now owns 8,983 shares of the company’s stock, valued at approximately $1,313,853.58. The disclosure for this sale can be found here. Insiders have sold 25,429 shares of company stock valued at $3,686,927 in the last quarter. 7.40% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SYK. Carnick & Kubik Group LLC purchased a new position in Stryker Corporation during the 1st quarter valued at approximately $1,016,000. Swiss National Bank grew its holdings in Stryker Corporation by 22.1% during the 1st quarter. Swiss National Bank now owns 1,502,071 shares of the medical technology company’s stock valued at $197,748,000 after buying an additional 272,300 shares in the last quarter. World Asset Management Inc grew its holdings in Stryker Corporation by 19.4% during the 1st quarter. World Asset Management Inc now owns 34,674 shares of the medical technology company’s stock valued at $4,565,000 after buying an additional 5,627 shares in the last quarter. UBS Asset Management Americas Inc. grew its holdings in Stryker Corporation by 10.4% during the 1st quarter. UBS Asset Management Americas Inc. now owns 1,026,598 shares of the medical technology company’s stock valued at $135,152,000 after buying an additional 97,027 shares in the last quarter. Finally, BARING ASSET MANAGEMENT Ltd grew its holdings in Stryker Corporation by 25.0% during the 1st quarter. BARING ASSET MANAGEMENT Ltd now owns 5,761 shares of the medical technology company’s stock valued at $758,000 after buying an additional 1,151 shares in the last quarter. Institutional investors and hedge funds own 74.13% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.